Antiretroviral Treatment (HAART) (SREBF1, drug side effects)

Infectiology

11.001

Antiretroviral Treatment (HAART) (SREBF1, drug side effects)

PHGN

Signs/symptoms:	nt3322C to G: risk factor for severe side effects in HIV treatment (AIDS 2001;15:2045) (PCT patent 02280, US patent pending; 10/030,504)
Complications:	Hyperlipidemia, atherosclerosis, coronary heart disease. Side effects of HIV-associated treatment.
Early diagnosis/treatment:	Yes

Material required:
Blood tubes:	EDTA whole blood (do not freeze, do not centrifugate)
Mouth brush:	Yes

Chromosomal localization:

17p11.2

OMIM number:

184756

Sterol-regulatory element-binding protein-1c

SREBF1c

Gene regions tested:
Gene regions:
Amino acid positions:
Nucleotide positions:	nt3322 C to G
Test methods:	Restriction Fragment Length

Prices:

Switzerland:

8820.00

8811.01

8818.00

	TP REVAL:	400	TP Value:	0.9	CHF	360.00
Other europe:	EUR					250.00
Other regions:	USD					call

References:

Miserez AR, Muller PY, Barella L, Schwietert M, Erb P, Vernazza PL, Battegay M; Swiss HIV Cohort Study. A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia. AIDS. 2001;15:2045-2049.

Miserez AR, Muller PY, Spaniol V. Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations. AIDS. 2002;16:1587-1594.

Browse Gene Tests

To view all our gene tests, please visit our Test Menu.

Antiretroviral Treatment (HAART) (SREBF1, drug side effects)